Clinical Trials

91 enrolled

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03340506 2026-04-01

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Neoplasms

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

220 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumors

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

DermatologicGastrointestinalHead & NeckThoracic

86 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

78 enrolled

Melanoma

NCT05874414 2026-01-22

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1/2 Recruiting

74 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

EGFR-mutant Non-small Cell Lung Cancer

NCT04452877 2026-01-13

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

40 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04111458 2026-01-12

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

71 enrolled

Solid Tumors, KRAS Mutation; SOS1

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

122 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03377361 2025-12-03

CheckMate 9N9

325 enrolled 31 charts

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT04940052 2025-12-02

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

153 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT05668585 2025-11-21

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

89 enrolled

Melanoma

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

260 enrolled

Plasma cell

Multiple Myeloma

NCT03551626 2025-04-29

COMBI-APlus

552 enrolled 12 charts

Fever, Melanoma

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1/2 Not yet recruiting

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05275374 2025-04-10

ENHANCE

221 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Phase 1/2 Terminated

9 enrolled 17 charts

Neoplasm Metastasis

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

151 enrolled 45 charts 2 FDA

CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

NCT01682083 2023-08-30

COMBI-AD

870 enrolled 13 charts 2 FDA

Melanoma, Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT04965220 2023-08-09

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Phase 1 Unknown

220 enrolled

Solid Tumor

NCT02130466 2022-08-01

MK-3475-022

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

177 enrolled 19 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

BreastGastrointestinalThoracic

283 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02705963 2022-02-09

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

19 enrolled

Solid Tumors

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT01750918 2021-10-29

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

166 enrolled 46 charts

Neoplasms, Colorectal Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

139 enrolled 42 charts 2 FDA

CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

Melanoma, Neoplasms

NCT01597908 2021-02-24

COMBI-v

704 enrolled 13 charts

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

423 enrolled 15 charts

Melanoma

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

95 enrolled

Pancreatic Neoplasms, Colorectal Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Other solid neoplasmThoracic

34 enrolled

Mesothelioma, Neoplasms

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

430 enrolled 61 charts

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

214 enrolled

Neoplasms

NCT02016729 2019-02-27

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Other hematologic neoplasm

36 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Melanoma, Neoplasms

NCT02258607 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

21 enrolled